Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Very Strong
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.2.9805.0488
Address
Suite 3.3 56 Delhi Road North Ryde, New South Wales (NSW) 2113
Description
Biotron Ltd. engages in the funding and management of research, development, and commercialization of drugs targeting significant viral diseases. It is developing the compound BIT225 for the treatment of HIV-1. The company was founded in February 1999 and is headquartered in North Ryde, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.03 - 0.12
Trade Value (12mth)
AU$66,194.00
1 week
-11.76%
1 month
-16.67%
YTD
-67.74%
1 year
-3.23%
All time high
0.43
EPS 3 yr Growth
-18.900%
EBITDA Margin
N/A
Operating Cashflow
-$3m
Free Cash Flow Return
-152.50%
ROIC
-161.90%
Interest Coverage
-1,138.20
Quick Ratio
4.20
Shares on Issue (Fully Dilluted)
902m
HALO Sector
Healthcare
Next Company Report Date
29-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
22 July 24 |
Application for quotation of securities - BIT
×
Application for quotation of securities - BIT |
11 July 24 |
Letter to Shareholders
×
Letter to Shareholders |
26 June 24 |
Webinar Investors Presentation
×
Webinar Investors Presentation |
25 June 24 |
BIOTRON CLINICAL TRIAL RESULTS WEBINAR
×
BIOTRON CLINICAL TRIAL RESULTS WEBINAR |
19 June 24 |
BIT225 Phase 2 HIV Efficacy Trial Meets Primary Objectives
×
BIT225 Phase 2 HIV Efficacy Trial Meets Primary Objectives |
23 May 24 |
Change of Share Registry address
×
Change of Share Registry address |
26 April 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
05 April 24 |
POSITIVE OUTCOMES IN BIT225 PHASE 2 CLINICAL TRIAL IN HIV
×
POSITIVE OUTCOMES IN BIT225 PHASE 2 CLINICAL TRIAL IN HIV |
27 March 24 |
Response to ASX Price Query
×
Response to ASX Price Query |
27 February 24 |
Half Yearly Report and Accounts
×
Half Yearly Report and Accounts |
08 February 24 |
$1.64M R&D rebate received
×
$1.64M R&D rebate received |
30 January 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
14 December 23 |
Shareholder Update
×
Shareholder Update |
01 December 23 |
Application for quotation of securities - BIT
×
Application for quotation of securities - BIT |
27 November 23 |
Notification of cessation of securities - BIT
×
Notification of cessation of securities - BIT |
27 November 23 |
Change of Director's Interest Notice MM
×
Change of Director's Interest Notice MM |
22 November 23 |
Presentation to Annual General Meeting
×
Presentation to Annual General Meeting |
22 November 23 |
Results of AGM
×
Results of AGM |
10 November 23 |
Application for quotation of securities - BIT
×
Application for quotation of securities - BIT |
27 October 23 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
26 October 23 |
Application for quotation of securities - BIT
×
Application for quotation of securities - BIT |
24 October 23 |
Presentation to Investors
×
Presentation to Investors |
20 October 23 |
Annual Report/Notice of Annual General Meeting/Proxy Form
×
Annual Report/Notice of Annual General Meeting/Proxy Form |
10 October 23 |
Application for quotation of securities - BIT
×
Application for quotation of securities - BIT |
29 September 23 |
Response to ASX Price Query
×
Response to ASX Price Query |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.